Tags

Type your tag names separated by a space and hit enter

The selective inhibition of the D₁ dopamine receptor results in an increase of metabolized dopamine in the rat striatum.
Neurochem Res 2012; 37(8):1783-9NR

Abstract

Our aim was to study the specific role of the postsynaptic D(1) receptors on dopaminergic response and analyze the metabolized dopamine (DA) in the rat striatum. We used male Wistar rats to evaluate the effects of different doses of a D(1) agonist (SKF-38393) and a D(1) antagonist (SCH-23390), and their co-administration. The levels of DA and L-3, 4-dihydroxyphenylacetic acid (DOPAC) were measured using high performance liquid chromatography. The systemic injection of SKF-38393 alone at 1, 5 and 10 mg/kg did not alter the DA and DOPAC levels or the DOPAC/DA ratio. In contrast, injection of SCH-23390 alone at 0.25, 0.5 and 1 mg/kg significantly increased the DA and DOPAC levels, as well as the DOPAC/DA ratio, compared with the respective control groups. The co-administration of SCH-23390+SKF-38393 did not alter the DA or DOPAC levels, but it did significantly inhibit the SCH-23390-induced increase of the DA and DOPAC levels. The SCH-23390+SKF-38393 and the SCH-23390-only groups showed an increase in the DOPAC/DA ratio. The co-administration of SCH-23390+PARGYLINE significantly decreased the DOPAC levels and the DOPAC/DA ratio compared with the control and SCH-23390 groups. Taken together, our results showed that selective inhibition with SCH-23390 produced an increase in metabolized DA via striatal monoamine oxidase. These findings also contribute to the understanding of the role of postsynaptic D(1) receptors in the long-loop negative feedback system in the rat striatum.

Authors+Show Affiliations

Doctorate Program in Biological Sciences, Universidad Autónoma Metropolitana Iztapalapa-Xochimilco, Calzada del Hueso 1100, Col Villa Quietud, D.F. 04960, Mexico. abueno@inr.gob.mxNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

22573387

Citation

Bueno-Nava, A, et al. "The Selective Inhibition of the D₁ Dopamine Receptor Results in an Increase of Metabolized Dopamine in the Rat Striatum." Neurochemical Research, vol. 37, no. 8, 2012, pp. 1783-9.
Bueno-Nava A, Gonzalez-Pina R, Alfaro-Rodriguez A, et al. The selective inhibition of the D₁ dopamine receptor results in an increase of metabolized dopamine in the rat striatum. Neurochem Res. 2012;37(8):1783-9.
Bueno-Nava, A., Gonzalez-Pina, R., Alfaro-Rodriguez, A., Avila-Luna, A., Arch-Tirado, E., & Alonso-Spilsbury, M. (2012). The selective inhibition of the D₁ dopamine receptor results in an increase of metabolized dopamine in the rat striatum. Neurochemical Research, 37(8), pp. 1783-9. doi:10.1007/s11064-012-0790-5.
Bueno-Nava A, et al. The Selective Inhibition of the D₁ Dopamine Receptor Results in an Increase of Metabolized Dopamine in the Rat Striatum. Neurochem Res. 2012;37(8):1783-9. PubMed PMID: 22573387.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - The selective inhibition of the D₁ dopamine receptor results in an increase of metabolized dopamine in the rat striatum. AU - Bueno-Nava,A, AU - Gonzalez-Pina,R, AU - Alfaro-Rodriguez,A, AU - Avila-Luna,A, AU - Arch-Tirado,E, AU - Alonso-Spilsbury,M, Y1 - 2012/05/10/ PY - 2011/12/01/received PY - 2012/04/27/accepted PY - 2012/04/14/revised PY - 2012/5/11/entrez PY - 2012/5/11/pubmed PY - 2012/11/6/medline SP - 1783 EP - 9 JF - Neurochemical research JO - Neurochem. Res. VL - 37 IS - 8 N2 - Our aim was to study the specific role of the postsynaptic D(1) receptors on dopaminergic response and analyze the metabolized dopamine (DA) in the rat striatum. We used male Wistar rats to evaluate the effects of different doses of a D(1) agonist (SKF-38393) and a D(1) antagonist (SCH-23390), and their co-administration. The levels of DA and L-3, 4-dihydroxyphenylacetic acid (DOPAC) were measured using high performance liquid chromatography. The systemic injection of SKF-38393 alone at 1, 5 and 10 mg/kg did not alter the DA and DOPAC levels or the DOPAC/DA ratio. In contrast, injection of SCH-23390 alone at 0.25, 0.5 and 1 mg/kg significantly increased the DA and DOPAC levels, as well as the DOPAC/DA ratio, compared with the respective control groups. The co-administration of SCH-23390+SKF-38393 did not alter the DA or DOPAC levels, but it did significantly inhibit the SCH-23390-induced increase of the DA and DOPAC levels. The SCH-23390+SKF-38393 and the SCH-23390-only groups showed an increase in the DOPAC/DA ratio. The co-administration of SCH-23390+PARGYLINE significantly decreased the DOPAC levels and the DOPAC/DA ratio compared with the control and SCH-23390 groups. Taken together, our results showed that selective inhibition with SCH-23390 produced an increase in metabolized DA via striatal monoamine oxidase. These findings also contribute to the understanding of the role of postsynaptic D(1) receptors in the long-loop negative feedback system in the rat striatum. SN - 1573-6903 UR - https://www.unboundmedicine.com/medline/citation/22573387/The_selective_inhibition_of_the_D₁_dopamine_receptor_results_in_an_increase_of_metabolized_dopamine_in_the_rat_striatum_ L2 - https://doi.org/10.1007/s11064-012-0790-5 DB - PRIME DP - Unbound Medicine ER -